Schrodinger Inc. (SDGR): Price and Financial Metrics

Schrodinger Inc. (SDGR): $19.37

0.52 (-2.61%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add SDGR to Watchlist
Sign Up

Industry: Medical - Services

Industry

C

Ranked

#61 of 61

in industry

SDGR Price/Volume Stats

Current price $19.37 52-week high $59.24
Prev. close $19.89 52-week low $19.32
Day low $19.32 Volume 161,564
Day high $19.84 Avg. volume 811,020
50-day MA $23.24 Dividend yield N/A
200-day MA $27.43 Market Cap 1.41B

SDGR Stock Price Chart Interactive Chart >


Schrodinger Inc. (SDGR) Company Bio


Schrödinger, Inc. provides chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development


SDGR Latest News Stream


Event/Time News Detail
Loading, please wait...

SDGR Latest Social Stream


Loading social stream, please wait...

View Full SDGR Social Stream

Latest SDGR News From Around the Web

Below are the latest news stories about SCHRODINGER INC that investors may wish to consider to help them evaluate SDGR as an investment opportunity.

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, December 19, 2023--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on December 13, 2023, the company granted (i) non-statutory stock options to purchase 1,800 shares of the company’s common stock to three newly hired employees and (ii) restricted stock units (RSUs) with respect to 2,250 shares of the company’s common stock to three newly hired employees. These grants were

Yahoo | December 19, 2023

Schrödinger Highlights Progress of Clinical Programs and Discloses Three New Programs at First Therapeutics Pipeline Investor Event

NEW YORK, December 14, 2023--Schrödinger is providing a detailed review of its proprietary drug discovery and development programs during its Pipeline Day.

Yahoo | December 14, 2023

Artificial Intelligence in Healthcare: 3 Stocks Transforming the Industry

Companies are applying AI in healthcare which is leading to better outcomes and stronger performance for their stocks.

Alex Sirois on InvestorPlace | December 11, 2023

Schrödinger Presents Data Supporting Advancement of SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting

NEW YORK, December 10, 2023--Schrödinger today announced new preclinical data on SGR-1505, its investigational MALT1 inhibitor, and SGR-2921, its investigational CDC7 inhibitor.

Yahoo | December 10, 2023

Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In November

The AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions.

TalkMarkets.com | December 6, 2023

Read More 'SDGR' Stories Here

SDGR Price Returns

1-mo -14.89%
3-mo -27.43%
6-mo -44.32%
1-year N/A
3-year -73.83%
5-year N/A
YTD -45.89%
2023 91.55%
2022 -46.34%
2021 -56.01%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!